

12 December 2022

## Oesophageal and Gastric Cancer

Information as available from RISOH (regional information system Oncology & Haematology)

### **Q1. Please provide the total number of patients treated in the last 3 months with any systemic anti-cancer therapy for:**

- Unfortunately we are only able to extract from the Regional Information System for Oncology and Haematology the basic cancer diagnosis.

Oesophageal cancer (any type or stage) **57**

- Oesophageal adenocarcinoma (any stage)
- Oesophageal squamous cell carcinoma (any stage)
- Gastric cancer (any type or stage) **40**
- Cancer of the gastro-oesophageal junction (any stage)

### **Q2. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:**

- CAPOX (Capecitabine with Oxaliplatin) **6**
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) **<5**
- Lonsurf (Trifluridine - tipiracil) **<5**
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) **<5**
- Any other systemic anti-cancer therapy **FLOT: 30, IMDG: <5, Nivolumab: <5**
- Palliative care only

### **Q3. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:**

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - **Pembrolizumab CX: <5, Pembrolizumab OX: <5**
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
  - **IMDG: <5, OX 80/375: 14, CX 60/625: 9, CX + XRT: <5, CX 60/625+Trazimera: 5, CX 80/1000+Trazimera: <5, OX 80/375+Trazimera: 5**
- Nivolumab monotherapy **480mg: <5, 240mg: <5**
- Nivolumab and Ipilimumab
- Any other systemic anti-cancer therapy
  - **Weekly Paclitaxel +Carboplatin: <5, Gemcitabine +Carboplatin: <5, Etoposide +Carboplatin: <5, Cisplatin +Etoposide: <5, CarboX +XRT: <5, Docetaxel: <5**
- Palliative care only

Q4. Of the Oesophageal Cancer patients (from Q3) treated with Pembrolizumab in the past 3 months, how many patients were treated for:

- **detail difficult to retrieve from RISOH system**

**12 December 2022**

- Oesophageal adenocarcinoma
- Oesophageal squamous cell carcinoma

Q5. How many patients were treated in the past 3 months for advanced/metastatic oesophageal cancer ONLY with:

- **detail difficult to retrieve from RISOH system.**
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
  - **Same as Q3 as only licenced for advanced cancer**
- Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- Nivolumab monotherapy
- Nivolumab and Ipilimumab
- Any other systemic anti-cancer therapy
- Palliative care only

**Please Note:**

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.